Arena Pharmaceuticals, Inc. Common Stock Quote & Summary Data
Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don’t know the stock symbol? Use the Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.
“Best Ask” is the lowest price currently being asked for a block of stock.
“Today’s Low” The lowest sales price the stock has fallen to during the regular trading hours, the intra-day low.
“52 Week Low” is the lowest sales price the stock has fallen to during the regular trading hours during the most recent 52 week period.
Prices during the When Issued trading period are used in the 52 week high/low calculation.
Company Description (as filed with the SEC)
We are a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first or best in class programs for which we own global commercial rights. Our three most advanced investigational clinical programs are etrasimod (formerly APD334) in Phase 2 evaluation for multiple inflammatory indications, ralinepag (formerly APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH), and APD371 entering Phase 2 evaluation for the treatment of pain associated with Crohn’s disease. Additionally, we have collaborations with the following pharmaceutical companies: Eisai Inc. and Eisai Co., Ltd. (collectively, Eisai) (commercial stage), Axovant Sciences Ltd., or Axovant, (Phase 2 candidate), and Boehringer Ingelheim International GmbH, or Boehringer Ingelheim, (preclinical candidate). . More .
Where does ARNA fit in the risk graph?